Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Anti-KIT Monoclonal Antibody Treatment Enhances the Antitumor Activity of Immune Checkpoint Inhibitors by Reversing Tumor-Induced Immunosuppression.

Garton AJ, Seibel S, Lopresti-Morrow L, Crew L, Janson N, Mandiyan S, Trombetta ES, Pankratz S, LaVallee TM, Gedrich R.

Mol Cancer Ther. 2017 Apr;16(4):671-680. doi: 10.1158/1535-7163.MCT-16-0676. Epub 2017 Jan 30.

2.

KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.

London CA, Gardner HL, Rippy S, Post G, La Perle K, Crew L, Lopresti-Morrow L, Garton AJ, McMahon G, LaVallee TM, Gedrich R.

Clin Cancer Res. 2017 May 15;23(10):2565-2574. doi: 10.1158/1078-0432.CCR-16-2152. Epub 2016 Nov 4.

3.

Discovery of a Highly Selective Glycogen Synthase Kinase-3 Inhibitor (PF-04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging.

Liang SH, Chen JM, Normandin MD, Chang JS, Chang GC, Taylor CK, Trapa P, Plummer MS, Para KS, Conn EL, Lopresti-Morrow L, Lanyon LF, Cook JM, Richter KE, Nolan CE, Schachter JB, Janat F, Che Y, Shanmugasundaram V, Lefker BA, Enerson BE, Livni E, Wang L, Guehl NJ, Patnaik D, Wagner FF, Perlis R, Holson EB, Haggarty SJ, El Fakhri G, Kurumbail RG, Vasdev N.

Angew Chem Int Ed Engl. 2016 Aug 8;55(33):9601-5. doi: 10.1002/anie.201603797. Epub 2016 Jun 29.

4.

Potent, selective spiropyrrolidine pyrimidinetrione inhibitors of MMP-13.

Freeman-Cook KD, Reiter LA, Noe MC, Antipas AS, Danley DE, Datta K, Downs JT, Eisenbeis S, Eskra JD, Garmene DJ, Greer EM, Griffiths RJ, Guzman R, Hardink JR, Janat F, Jones CS, Martinelli GJ, Mitchell PG, Laird ER, Liras JL, Lopresti-Morrow LL, Pandit J, Reilly UD, Robertson D, Vaughn-Bowser ML, Wolf-Gouviea LA, Yocum SA.

Bioorg Med Chem Lett. 2007 Dec 1;17(23):6529-34. Epub 2007 Sep 29.

PMID:
17935984
5.

Potent, selective pyrimidinetrione-based inhibitors of MMP-13.

Reiter LA, Freeman-Cook KD, Jones CS, Martinelli GJ, Antipas AS, Berliner MA, Datta K, Downs JT, Eskra JD, Forman MD, Greer EM, Guzman R, Hardink JR, Janat F, Keene NF, Laird ER, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robertson D, Sperger D, Vaughn-Bowser ML, Waller DM, Yocum SA.

Bioorg Med Chem Lett. 2006 Nov 15;16(22):5822-6. Epub 2006 Aug 30.

PMID:
16942871
6.

Discovery of 3-OH-3-methylpipecolic hydroxamates: potent orally active inhibitors of aggrecanase and MMP-13.

Noe MC, Natarajan V, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Otterness I, Bliven MA, Carty TJ, Barberia JT, Sweeney FJ, Liras JL, Vaughn M.

Bioorg Med Chem Lett. 2005 Jul 15;15(14):3385-8.

PMID:
15953722
7.

Discovery of 3,3-dimethyl-5-hydroxypipecolic hydroxamate-based inhibitors of aggrecanase and MMP-13.

Noe MC, Natarajan V, Snow SL, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Carty TJ, Barberia JA, Sweeney FJ, Liras JL, Vaughn M, Hardink JR, Hawkins JM, Tokar C.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2808-11.

PMID:
15911259
8.

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.

Blagg JA, Noe MC, Wolf-Gouveia LA, Reiter LA, Laird ER, Chang SP, Danley DE, Downs JT, Elliott NC, Eskra JD, Griffiths RJ, Hardink JR, Haugeto AI, Jones CS, Liras JL, Lopresti-Morrow LL, Mitchell PG, Pandit J, Robinson RP, Subramanyam C, Vaughn-Bowser ML, Yocum SA.

Bioorg Med Chem Lett. 2005 Apr 1;15(7):1807-10.

PMID:
15780611
9.

3-Hydroxy-4-arylsulfonyltetrahydropyranyl-3-hydroxamic acids are novel inhibitors of MMP-13 and aggrecanase.

Noe MC, Snow SL, Wolf-Gouveia LA, Mitchell PG, Lopresti-Morrow L, Reeves LM, Yocum SA, Liras JL, Vaughn M.

Bioorg Med Chem Lett. 2004 Sep 20;14(18):4727-30.

PMID:
15324896
10.

Pyran-containing sulfonamide hydroxamic acids: potent MMP inhibitors that spare MMP-1.

Reiter LA, Robinson RP, McClure KF, Jones CS, Reese MR, Mitchell PG, Otterness IG, Bliven ML, Liras J, Cortina SR, Donahue KM, Eskra JD, Griffiths RJ, Lame ME, Lopez-Anaya A, Martinelli GJ, McGahee SM, Yocum SA, Lopresti-Morrow LL, Tobiassen LM, Vaughn-Bowser ML.

Bioorg Med Chem Lett. 2004 Jul 5;14(13):3389-95.

PMID:
15177439
11.

Synthesis and biological activity of piperazine-based dual MMP-13 and TNF-alpha converting enzyme inhibitors.

Letavic MA, Barberia JT, Carty TJ, Hardink JR, Liras J, Lopresti-Morrow LL, Mitchell PG, Noe MC, Reeves LM, Snow SL, Stam EJ, Sweeney FJ, Vaughn ML, Yu CH.

Bioorg Med Chem Lett. 2003 Oct 6;13(19):3243-6.

PMID:
12951101
12.

Phosphinic acid-based MMP-13 inhibitors that spare MMP-1 and MMP-3.

Reiter LA, Mitchell PG, Martinelli GJ, Lopresti-Morrow LL, Yocum SA, Eskra JD.

Bioorg Med Chem Lett. 2003 Jul 21;13(14):2331-6.

PMID:
12824028
13.

Synthesis and biological activity of selective pipecolic acid-based TNF-alpha converting enzyme (TACE) inhibitors.

Letavic MA, Axt MZ, Barberia JT, Carty TJ, Danley DE, Geoghegan KF, Halim NS, Hoth LR, Kamath AV, Laird ER, Lopresti-Morrow LL, McClure KF, Mitchell PG, Natarajan V, Noe MC, Pandit J, Reeves L, Schulte GK, Snow SL, Sweeney FJ, Tan DH, Yu CH.

Bioorg Med Chem Lett. 2002 May 20;12(10):1387-90.

PMID:
11992783
14.

Selective matrix metalloproteinase inhibition reduces left ventricular remodeling but does not inhibit angiogenesis after myocardial infarction.

Lindsey ML, Gannon J, Aikawa M, Schoen FJ, Rabkin E, Lopresti-Morrow L, Crawford J, Black S, Libby P, Mitchell PG, Lee RT.

Circulation. 2002 Feb 12;105(6):753-8.

15.

Design and synthesis of 2-oxo-imidazolidine-4-carboxylic acid hydroxyamides as potent matrix metalloproteinase-13 inhibitors.

Robinson RP, Laird ER, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Rouch AI, Stam EJ, Yocum SA.

Bioorg Med Chem Lett. 2001 May 7;11(9):1211-3.

PMID:
11354379
16.

Structure-based design and synthesis of a potent matrix metalloproteinase-13 inhibitor based on a pyrrolidinone scaffold.

Robinson RP, Laird ER, Blake JF, Bordner J, Donahue KM, Lopresti-Morrow LL, Mitchell PG, Reese MR, Reeves LM, Stam EJ, Yocum SA.

J Med Chem. 2000 Jun 15;43(12):2293-6. No abstract available.

PMID:
10882354
17.

MMP-13 and MMP-1 expression in tissues of normal articular joints.

Yocum SA, Lopresti-Morrow LL, Reeves LM, Mitchell PG.

Ann N Y Acad Sci. 1999 Jun 30;878:583-6. No abstract available.

PMID:
10415780
18.

New Insights into Disintegrin Metalloproteases.

Carty TJ, LoPresti-Morrow LL, Mitchell PG, McNiff PA, McClure KF.

Inflamm Res. 1999 May;48(5):229-31. No abstract available.

PMID:
10391108
19.

Inhibition of MMP-1 and MMP-13 with phosphinic acids that exploit binding in the S2 pocket.

Reiter LA, Rizzi JP, Pandit J, Lasut MJ, McGahee SM, Parikh VD, Blake JF, Danley DE, Laird ER, Lopez-Anaya A, Lopresti-Morrow LL, Mansour MN, Martinelli GJ, Mitchell PG, Owens BS, Pauly TA, Reeves LM, Schulte GK, Yocum SA.

Bioorg Med Chem Lett. 1999 Jan 18;9(2):127-32.

PMID:
10021913
20.

Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage.

Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow LL, Yocum SA, Rosner PJ, Geoghegan KF, Hambor JE.

J Clin Invest. 1996 Feb 1;97(3):761-8.

21.

Bafilomycin A1 inhibits IL-1-stimulated proteoglycan degradation by chondrocytes without affecting stromelysin synthesis.

Yocum SA, Lopresti-Morrow LL, Gabel CA, Milici AJ, Mitchell PG.

Arch Biochem Biophys. 1995 Feb 1;316(2):827-35.

PMID:
7864640
22.

Inhibition of interleukin-1-stimulated collagen degradation in cartilage explants.

Mitchell PG, Lopresti-Morrow L, Yocum SA, Sweeney FJ, Reiter LA.

Ann N Y Acad Sci. 1994 Sep 6;732:395-7. No abstract available.

PMID:
7978818
23.

Deficiency of alpha-spectrin synthesis in burst-forming units-erythroid in lethal hereditary spherocytosis.

Whitfield CF, Follweiler JB, Lopresti-Morrow L, Miller BA.

Blood. 1991 Dec 1;78(11):3043-51.

Supplemental Content

Loading ...
Support Center